Reply: Relative efficacy of intracameral moxifloxacin injection methods

J Cataract Refract Surg. 2023 Oct 1;49(10):1080-1081. doi: 10.1097/j.jcrs.0000000000001263.

Authors

Steve A Arshinoff¹, Runjie B Shi

Affiliation

¹ From the York Finch Eye Associates, Toronto, Ontario, Canada (Arshinoff); Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada (Arshinoff); Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada (Shi); Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (Shi).

PMID: 37769177
DOI: 10.1097/j.jcrs.0000000000001263

No abstract available

Publication types

Letter
Comment

MeSH terms

Anterior Chamber
Anti-Bacterial Agents* / therapeutic use
Antibiotic Prophylaxis
Endophthalmitis* / drug therapy
Endophthalmitis* / prevention & control
Fluoroquinolones
Humans
Moxifloxacin

Substances

Moxifloxacin
Anti-Bacterial Agents
Fluoroquinolones